On June 30, 2021 Incurix reported that the company in-licensed the STAT3 inhibitor anti-cancer substance from the National Cancer Center (NCC) and the Korea Research Institute of Chemical Technology (KRICT) (Press release, Korea Research Institute of Chemical Technology, JUN 30, 2021, View Source;idx=71&page=1&code=news [SID1234643572]). The agreement is the second after last year’s in-licensing of the c-myc inhibitor. Company officials explained that securing another pipeline of new transcription factor inhibitor is meaningful, following the c-myc inhibitor ‘ICX-101,’ currently in pre-clinical studies. As a transcription factor that controls cell development, survival and immune function, STAT3 is known to be over-expressed in several cancers, causing tumor formation and metastasis. The direct inhibitor of STAT3 is yet to be developed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Through Incurix’s differentiated new drug development know-hows and system, we will succeed in developing an additional transcription factor targeting anti-cancer drug that we in-licensed," Incurix CEO Kyung-chae Jeong said. Meanwhile, Incurix was founded by NCC Senior Director Dr. Kyung-Chae Jeong. The newly licensed compound is a new target anti-cancer substance that Dr. Jeong co-developed with Hwan-jung Lim, Head of New Drug Pipeline Research at KRICT, and Senior Researcher Sung-joon Park.